Author

A.-K. Jochum

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

L. Flatz· 3 shared O. H. Ali· 2 shared W. Jochum· 2 shared A. Aggarwal· 1 shared A. J. Cole· 1 shared A. Muenster-Kuehnel· 1 shared A. O. Stella· 1 shared A. Obenauf· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPathology

L. Flatz

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19

N. A. Lengacher, J. J. Tomlinson, A.-K. Jochum, J. Franz, O. Hasan Ali, L. Flatz, W. Jochum, J. Penninger, aSCENT-PD Investigators, C. Stadelmann-Nessler, J. M. Woulfe, M. G. Schlossmacher

This study examines neuropathological changes in the olfactory bulb and tract of COVID-19 patients, finding no significant inflammation but age-related decline in anti-CD68 reactivity and mild increases in phospho-Syn and phospho-tau signals in affected brains.

bioRxiv · Dec 18, 2023Pathology

Tumor sialylation controls effective anti-cancer immunity in breast cancer

S. Mereiter, G. Jonsson, T. Oliveira, J. Helm, D. Hoffmann, M. Abeln, A.-K. Jochum, W. Jochum, M. J. Kellner, M. Feith, V. Tkalec, K. Wasilewska, J. Jiao, L. Emsenhuber, F. Holstein, , J. M. Penninger

This study shows that tumor sialylation suppresses anti-cancer immunity in breast cancer by altering immune cell interactions and checkpoint ligands, and that inhibiting sialylation enhances immune response and therapy effectiveness.

bioRxiv · Sep 20, 2023 · PreprintCancer Biology

Fibroblast-expressed LRRC15 suppresses SARS-CoV-2 infection and controls antiviral and antifibrotic transcriptional programs.

L. Loo, M. A. Waller, C. L. Moreno, A. J. Cole, A. O. Stella, O.-T. Pop, A.-K. Jochum, O. H. Ali, C. E. Denes, Z. Hamoudi, F. Chung, A. Aggarwal, J. K. K. Low, K. Patel, R. Siddique, , G. G. Neely

This study identifies LRRC15 as a host factor that suppresses SARS-CoV-2 infection and regulates antiviral and antifibrotic transcriptional programs in fibroblasts.

bioRxiv · Nov 9, 2021 · PreprintCell Biology